why choose us

First received: December 08, 2022

Clinical Trial: CardioSeq: Impact of WGS in Individuals With CVD

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cardiovascular Diseases

Study Type: INTERVENTIONAL


Official Title: CardioSeq: A Prospective, Single-Center, Open-label Study to Evaluate the Impact of Whole Genome Sequencing (WGS) in Individuals With Cardiovascular Disease

Brief Summary: This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease.Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.

Read more